Hepatitis C Combination Therapy Seeks Label Update

Article

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Olysio was originally approved in November 2014 for use with Gilead’s sofosbuvir (Solvadi) in adults with genotype 1 chronic HCV infection. The FDA approved this combination treatment regimen for 12 weeks in such patients without cirrhosis or 24 weeks in those with cirrhosis.

Now, Janssen has submitted a supplemental New Drug Application based on results from the phase 3 OPTIMIST-1 and OPTIMIST-2 trials.

OPTIMIST-1 showed sustained virologic response (SVR) in treatment-naive and treatment-experienced genotype 1 CHC patients without cirrhosis at 12 weeks after treatment (SVR12) with 12 and 8 weeks of Olysio and Solvadi treatment compared with a control group of patients previously treated with approved regimens containing a direct-acting antiviral, pegylated interferon, and ribavirin.

Similar results were seen in OPTIMIST-2, this time in treatment-naive and treatment-experienced genotype 1 CHC patients with cirrhosis.

“Olysio has contributed significantly to the care of people living with hepatitis C,” stated Richard Nettles, vice president of medical affairs at Janssen Therapeutics. “The availability of multiple treatment options is important to help offer an opportunity for cure, and we believe Olysio will continue to play a meaningful role going forward.”

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.